论文部分内容阅读
目的:观察舒洛地特对2型糖尿病早期肾病的治疗作用。方法:144例不伴高血压的2型糖尿病早期肾病患者,代谢控制稳定后,原糖尿病治疗方案不变,随机分为常规治疗组、舒洛地特治疗组、苯那普利治疗组及舒洛地特+苯那普利治疗组。观察治疗前、治疗4周、治疗12周,尿白蛋白/尿肌酐(ACR)的变化,同时观察空腹血糖、糖化血红蛋白、血总胆固醇、血甘油三酯、血肌酐、纤维蛋白原的变化。结果:除常规治疗组外,其他三组治疗12周前后的ACR比较均有统计学差异(P<0.01)。治疗12周后,舒洛地特治疗组、苯那普利治疗组、舒洛地特+苯那普利治疗组与常规治疗12周后相比,ACR下降有统计学差异(P<0.01),但3组间治疗后12周的差异无统计学意义(P>0.05)。结论:舒洛地特能减少2型糖尿病早期肾病的ACR,延缓肾病的进展,是一种新的治疗糖尿病肾病的途径。
Objective: To observe the therapeutic effect of sulodexide on type 2 diabetic nephropathy. Methods: One hundred and forty-four patients with type 2 diabetes without early-stage nephropathy without hypertension were divided into routine treatment group, sulodentiide treatment group, benazepril treatment group and Shu Lotot + benazepril treatment group. The changes of urinary albumin / creatinine (ACR) were observed before treatment, 4 weeks after treatment and 12 weeks after treatment. Meanwhile, the changes of fasting blood glucose, glycosylated hemoglobin, total cholesterol, triglyceride, serum creatinine and fibrinogen were observed. Results: In addition to the conventional treatment group, the other three groups before and after treatment for 12 weeks ACR were statistically significant differences (P <0.01). After 12 weeks of treatment, there was a significant difference (P <0.01) in the ACR reduction between the sulodexide group, the benazepril treatment group, the sulodexide and the benazepril treatment group after 12 weeks of treatment, , But there was no significant difference in the 12 weeks after treatment between the three groups (P> 0.05). CONCLUSIONS: It is a new way to treat diabetic nephropathy that sulodentia can reduce the ACR of type 2 diabetic nephropathy and delay the progression of nephropathy.